Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy

SIMPLE SUMMARY: Since the recent approval of osimertinib, a third generation tyrosine kinase inhibitor (TKI) targeting EGFR in non-small cell lung cancer (NSCLC), tracing the resistance mechanisms that yield to failure of osimertinib has become of interest. As the spectrum of osimertinib-resistance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Jóri, Balázs, Schatz, Stefanie, Kaller, Len, Kah, Bettina, Roeper, Julia, Ramdani, Hayat O., Diehl, Linda, Hoffknecht, Petra, Grohé, Christian, Griesinger, Frank, Tiemann, Markus, Heukamp, Lukas C., Falk, Markus
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8227553/
https://ncbi.nlm.nih.gov/pubmed/34201252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13122861
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados